|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Hisashi Ietsugu||Chairman of the Managing Board & CEO||210M||N/D||1949|
|Mr. Chris Cappella||Chief Financial Officer||N/D||N/D||N/D|
|Mr. Kaoru Asano||CTO, Sr. MD, Sr. Exec. Officer, Sr. MD & Member of the Managing Board||N/D||N/D||1958|
|Mr. Iwane Matsui||MD of Global Marketing, Sr. Exec. Officer & Member of Managing Board||N/D||N/D||1961|
|Mr. Kenji Tachibana||Sr. MD of Corp Mgmt & Regulatory Affairs, Sr. Exec. Officer & Member of the Managing Board||N/D||N/D||1957|
|Mr. Hiroshi Kanda||MD of Bus. Strategy Devel., Sr. Exec. Officer & Member of the Managing Board||N/D||N/D||1957|
|Mr. Mamoru Kubota||Sr. Exec. Officer & Deputy in charge of Bus. Strategy Devel.||N/D||N/D||N/D|
|Mr. Kensuke Lizuka||Sr. Exec. Officer & Exec. VP of Corp. Bus. Planning Div.||N/D||N/D||N/D|
|Mr. Tomokazu Yoshida||Sr. Exec. Officer, MD of R&D, Incubation & MR Bus. and Member of the Managing Board||N/D||N/D||1964|
|Mr. Takashi Ono||Sr. Exec. Officer||N/D||N/D||N/D|
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
L'ISS Governance QualityScore di Sysmex Corporation al 28 gennaio 2023 è 4. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 3; retribuzione: 1.